Wedbush maintains Tyra Biosciences at Outperform, raises price target to $57 from $53
Wedbush reaffirmed its Outperform rating for Tyra Biosciences and increased its price target to $57 from $53, representing a 7.5% rise. This target suggests a potential 171.4% upside from the Nov 10 closing price of $21, according to the firm.


